Information Provided By: 
Fly News Breaks for March 29, 2019
TGTX
Mar 29, 2019 | 07:00 EDT
Cantor Fitzgerald analyst Alethia Young initiated coverage of TG Therapeutics with an Overweight rating and $17 price target. The analyst believes umbralisib and ublituximab have attractive profiles in oncology and autoimmune B-cell diseases. Investors are cautious on the PI3K commercial potential and give no credit to multiple sclerosis due to the competitive yet price sensitive landscape, but both lead assets as clinically de-risked with proven targets, Young tells investors in a research note. She thinks the risk/reward on TG shares is positive.
News For TGTX From the Last 2 Days
There are no results for your query TGTX
